Kyle LaHucik
How bluebird’s buyout offer went from $100M upfront to $29M
Bluebird bio went from a high-flying $10 billion company in 2018 during the heyday of gene therapy to…
En vogue Chinese ADC biotech lets Hong Kong IPO filing lapse
Duality Biologics, an ADC startup that’s attracted multiple biopharma partnerships, has let its plans to list on the…
How Keymed steered the China-to-US NewCo model in biotech
Keymed Biosciences is a prime example of a young Chinese biotech churning out pipeline candidates ripe for out-licensing…
Newleos, a new biotech with $93.5M, repurposes Roche’s experimental CNS drugs
Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from…
Metsera outlines $250M IPO plans as obesity biotech competition rises
Metsera, a well-funded biotech trying to angle toward the front of the obesity medicine pack, has proposed a…
Obesity biotech Aardvark files for IPO to advance oral, hunger-suppressing drug
Aardvark Therapeutics filed for an IPO Thursday night, making it the sixth biotech in line this year for…
Aiolos team reunites with $411M for new biotech with obesity drugs from China
Khurem Farooq, Verdiva Bio CEO January 9, 2025 02:00 AM EST FinancingStartupsR&D Aiolos team reunites with $411M for…
Maze files for first biotech IPO of 2025, following $115M funding boost
Maze Therapeutics has submitted its pitch for an initial public offering after disclosing a $115 million Series D…
Exclusive: Forbion-backed cardio biotech rebrands to RyCarma with Phase 2 plans
Adam Rosenberg, RyCarma Therapeutics CEO January 7, 2025 05:30 AM EST PeopleStartups Exclusive: Forbion-backed cardio biotech rebrands to…
Exclusive: Florida cancer biotech raises $100M Series A
Syncromune, a biotech startup working on combination immunotherapies, has put together a $100 million Series A, the company…
SiteOne Therapeutics, a pain biotech that’s partnered with Vertex, nabs $100M
About eight years after its Series B, a small biotech working on non-opioid treatments has raised its Series…
Chicago’s biotech scene is growing up. What’s fueling it?
CHICAGO — Over the years, a handful of cities have tried catching up to the flourishing biotech hubs…
Exclusive: Cell therapy startup Shinobi adds Borges as science chief, Katz as top medical officer
Shinobi Therapeutics, an off-the-shelf cell therapy developer, told Endpoints News it has hired its first chief scientific and…
New oncology biotech launches with $52M in its pocket
From left to right Tasca Therapeutics co-founders David Fisher, Milenko Cicmil, Xu Wu (Credit: Rick Bern Photography) December…
Dutch biotech nabs €85M to position inflammatory antibody for a pharma buyer
Citryll, a Dutch biotech that has largely flown under the radar for most of its nearly 10-year history,…
